Related Experiment Videos
In-vivo effects of clindamycin on neutrophil function
Abstract:
Neutrophil functions were evaluated in 13 normal subjects who had received 300 mg of clindamycin orally four times each day for two days. The mean serum concentration of clindamycin was 1.6 mg/l. Intracellular killing of a clindamycin-resistant strain of Staphylococcus aureus increased from 38% to 45%, P less than 0.005, during clindamycin therapy. In contrast, clindamycin therapy did not significantly alter chemotaxis, phagocytosis, chemiluminescence of neutrophils, or the ability of serum to generate chemotactic factor and opsonize particles of yeast. The potentially synergistic relationship between clindamycin and neutrophils may prove to be valuable for the treatment of staphylococcal infections in patients with defects in oxygen-dependent mechanism of neutrophil-mediated bacterial killing such as in chronic granulomatous disease.
Insights
Clindamycin therapy enhanced neutrophils' ability to kill Staphylococcus aureus. This finding suggests a potential benefit for treating staphylococcal infections, especially in patients with impaired neutrophil function.
Area of Science:
- Immunology
- Pharmacology
- Infectious Diseases
Background:
- Neutrophils are critical immune cells for combating bacterial infections.
- Clindamycin is an antibiotic commonly used to treat bacterial infections.
- Understanding drug-host interactions is vital for optimizing therapeutic strategies.
Purpose of the Study:
- To investigate the effects of oral clindamycin on neutrophil functions.
- To assess the impact of clindamycin on the intracellular killing of Staphylococcus aureus.
- To explore the potential synergistic relationship between clindamycin and neutrophils.
Main Methods:
- 13 healthy subjects received oral clindamycin (300 mg, four times daily for two days).
- Neutrophil functions including intracellular killing, chemotaxis, phagocytosis, and chemiluminescence were evaluated.
- Serum's ability to generate chemotactic factor and opsonize yeast particles was assessed.
Main Results:
- Neutrophil intracellular killing of a clindamycin-resistant Staphylococcus aureus strain significantly increased (38% to 45%, P < 0.005).
- Clindamycin therapy did not significantly alter neutrophil chemotaxis or phagocytosis.
- No significant changes were observed in neutrophil chemiluminescence or serum-mediated opsonization and chemotaxis generation.
Conclusions:
- Clindamycin enhances the intracellular killing capacity of neutrophils against Staphylococcus aureus.
- The findings suggest a potential synergistic effect between clindamycin and neutrophils.
- This interaction may be beneficial for treating staphylococcal infections in patients with compromised neutrophil-mediated bacterial killing, such as in chronic granulomatous disease.